Cost-benefit of stockpiling drugs for influenza pandemic
- PMID: 16102319
- PMCID: PMC3320484
- DOI: 10.3201/eid1108.041156
Cost-benefit of stockpiling drugs for influenza pandemic
Abstract
We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.
Figures
References
-
- WHO consultation on priority public health interventions before and during an influenza pandemic, Geneva, 16–18 March 2004. Wkly Epidemiol Rec. 2004;79:107–8. - PubMed
-
- Cohen Y. Tamiflu pharmaco-economic dossier, part C: evaluation of influenza cost of illness in Israel. Natanya (Israel): Quintiles Israel; 2000. p. 1–46.
-
- Statistical abstract of Israel 2003, no. 54. Jerusalem: Israel Central Bureau of Statistics; 2003.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical